Advanced search
Publication Cover
Cancer Management and Research Volume 11, 2019 - Issue
Submit an article Journal homepage
55
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods

Hong-Mei ZhangDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of China
,
Xi-Yang LiuDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of China
,
Yu-Zhang LiuDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of China
,
Li-Na LiuDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of China
,
Quan-De LinDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of China
,
Yong-Ping SongDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of China
&
Bai-Jun FangDepartment of Hematology, Henan Institute of Haematology, Henan Cancer Hospital, the Affliated Cancer Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou450008, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 8295-8302 | Published online: 10 Sep 2019

Figures & data

Table 1 Baseline characteristics of patients in the IV group and the SC group

Table 2 The response after every cycle

Figure 1 Comparison of progression-free survival for MM patients treated by bortezomib through different administration methods.

Figure 1 Comparison of progression-free survival for MM patients treated by bortezomib through different administration methods.

Figure 2 Comparison of overall survival for MM patients treated by bortezomib through different administration methods.

Figure 2 Comparison of overall survival for MM patients treated by bortezomib through different administration methods.

Table 3 Summary of other adverse events

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.